Authors: (Anne-Marie Kappelgaard, Global Marketing GHT, Novo Nordisk A/S, Vandtårnsvej, Søborg, Denmark)
Abstract: The key objective of growth hormone (GH) treatment in children with short stature is to improve growth velocity in childhood and achieve an adult height within their target height range. Apart from short stature, GH therapy is also associated with improving bone mineral density and reducing the risk of cardiovascular and metabolic complications that may persist into adult life (Clayton et al. 2005).
To achieve optimum benefits from GH treatment it is essential that patients follow their prescribed regimens from their healthcare providers (HCPs). Patients may, however, find the overall treatment management process onerous, since it involves daily self-administered injections, often started at a very young age and continuing at least until adult height is achieved, and sometimes for life. Achieving optimal patient adherence is therefore a challenge. Misperceptions about the consequences of missed doses, lack of dialogue between patients/carers and HCPs, type of delivery systems and discomfort with injections may all impact on patient preference and acceptance of treatment.
The overall treatment burden may be reduced by providing patients with adequate support and education about their treatment as well as providing them with products that are easier to use thereby improving patient adherence to treatment. The objective of this review is to examine the issues and potential solutions for underachieved outcomes in GH-treated patients, with particular emphasis on recent advances in GH administration devices.